

Risk Factors and Prognostic Implications of New-Onset Paroxysmal Atrial Fibrillation in Patients Hospitalized with Intracerebral Hemorrhage

Baozi Huang^{1,2}, Jianle Li¹, Pingping Li^{1,2}, Chunyong Chen^{1,2}, Suhan Cao¹, Zimu Jiang¹, Jinsheng Zeng¹

¹Department of Neurology and Stroke Center, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, The First Affiliated Hospital, Sun Yat-sen University, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, People's Republic of China; ²Department of Neurology of the First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China

Correspondence: Jinsheng Zeng, Department of Neurology and Stroke Center, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, The First Affiliated Hospital, Sun Yat-sen University, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou, 510080, People's Republic of China, Tel +86-20-87755766-8253, Fax +86-20-87335935, Email zengjsh@mail.sysu.edu.cn

Objective: We aimed to assess the prevalence and risk factors of new-onset paroxysmal atrial fibrillation (PAF) in patients hospitalized with ICH and determine whether the new-onset PAF had influenced functional outcomes.

Methods: We analyzed a database of all consecutive patients with ICH from October 2013 to May 2022. Univariate and multivariable regression analyses were performed to identify risk factors for new-onset PAF in patients with ICH. Multivariate models were also constructed to assess whether the new-onset PAF was an independent predictor of poor functional outcome, as measured using the modified Rankin scale.

Results: This study included 650 patients with ICH, among whom 24 patients had new-onset PAF. In the multivariable model, older age (OR per 10-y increase, 2.26 [95% CI, 1.52–3.35]; $P<0.001$), hematoma volume (OR per 10-mL increase, 1.80 [95% CI, 1.26–2.57]; $P=0.001$), and heart failure (OR, 21.77 [95% CI, 5.52–85.91]; $P<0.001$) were independent risk factors for new-onset PAF. In a sensitivity analysis restricted to 428 patients with N-terminal pro-B-type natriuretic peptide (NT-proBNP), older age, larger hematoma volume, heart failure, and increased NT-proBNP were associated with new-onset PAF. After adjusting for baseline variables, new-onset PAF was an independent predictor of poor functional outcome (OR, 10.35 [95% CI, 1.08–98.80]; $P=0.042$).

Conclusion: Older age, larger hematoma volume, and heart failure were independent risk factors for new-onset PAF after ICH. Increased NT-proBNP is correlated with higher risks for new-onset PAF when their information is available at admission. Furthermore, new-onset PAF is a significant predictor of poor functional outcome.

Keywords: intracerebral hemorrhage, paroxysmal atrial fibrillation, prognostic implication, risk factors

Introduction

Atrial fibrillation (AF) is a significant risk factor for cardioembolic stroke.¹ Among patients with embolic stroke of undetermined source (ESUS), paroxysmal AF (PAF) is considered to be the main underlying cause and is detected in 10–30% of these patients.^{2,3} Timely detection of PAF after acute ischemic stroke (AIS) has meaningful therapeutic implications; therefore, predictors of PAF in patients with AIS have been widely investigated.^{4–7} However, limited data are available regarding the prevalence and risk factors of new-onset PAF after intracerebral hemorrhage (ICH), rather than patients with an ICH secondary to AIS. The rates of new AF in patients with ICH reportedly range from 2.6% to 6%; however, these studies were limited by classifying AF patterns and no risk factor verification.^{8–10} Newly diagnosed AF during hospitalization is independently related to an unfavorable 3-month outcome among patients with a cardioembolic stroke.¹¹ Nevertheless, whether this new-onset, transient, and accidentally discovered AF is associated with poor functional outcome in patients with ICH remains unknown. Thus, this study aimed to investigate the

prevalence and risk factors of new-onset PAF in patients who were hospitalized for ICH and assess the association between new-onset PAF and functional outcomes at discharge.

Methods

Patient Selection

This study enrolled consecutive patients diagnosed with ICH at the First Affiliated Hospitals of Sun Yat-sen University between October 2013 and May 2022. All study procedures were approved by the independent ethics committee of the First Affiliated Hospitals of Sun Yat-sen University, and obtaining informed consent from patients was not required due to its retrospective nature. The inclusion criteria were (1) Age ≥ 18 years; (2) Evidence of cerebral hemorrhage on head computed tomography (CT); (3) Onset time of less than 7 days; (4) At least 24 hours of continuous stroke unit electrocardiography monitoring (CEM); and (5) Modified Rankin Scale (mRS) score ≤ 1 prior to ICH. Patients were excluded if they met one or more of the following criteria: (1) Surgery before admission; (2) Hospital stay less than 24 hours; (3) Post-cardiopulmonary resuscitation; (4) History of AF; (5) Traumatic ICH; (6) A recent cerebral ischemia (< 3 months); and (7) Isolated intraventricular hemorrhage (IVH).

Data Collection

Baseline clinical information, including gender, age, systolic blood pressure (SBP), pneumonia, surgical interventions, intensive care unit (ICU) admission, duration of CEM, and length of hospital stay were extracted. Blood tests on admission were available for creatinine, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and glucose levels. Hypertension was defined as a medical history of hypertension or systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90 mm. Diabetes mellitus was defined by a fasting blood glucose ≥ 7.0 mmol/L or postprandial blood glucose ≥ 11.1 mmol/L or HbA1c $\geq 7\%$ or a medical history of diabetes. Smoking status was based on self-report and defined as current smoker, never smoker, or past smoker. Coronary heart disease was defined as a medical history of myocardial infarction or coronary revascularization.¹² Heart failure was defined by the presence of symptoms and signs of heart failure, and one of the following diagnostic criteria: a plasma NT-proBNP ≥ 125 ng/L or a left ventricular ejection fraction (LVEF) $\leq 40\%$.¹³

AF episodes were evaluated by CEM with an automated detection of AF. All episodes of AF were confirmed by a trained neurologist and classified as having paroxysmal or sustained AF according to the 2010 European Society of Cardiology guidelines for the management of AF.¹⁴ We defined new-onset PAF as AF that was detected during the hospitalization of patients who had no history of AF and that terminated spontaneously within 7 days of onset.

The baseline head CT was assessed by two independent neurologists. We determined the location of the insula based on the identification of the Alberta stroke program early CT score region.¹⁵ We considered that the insula was damaged when it was directly involved or deformation was caused by the mass effect of ICH.¹⁰ Hematoma location was determined and classified as follows: lobar (occipital, parietal, temporal, and frontal), deep (basal ganglia and thalamus), and infratentorial (cerebellar and brainstem). The ABC/2 method was used to measure the hematoma volume.¹⁶ In addition, the presence of IVH and/or subarachnoid hemorrhage (SAH) was documented.

Evaluation of Clinical Outcomes

The Glasgow Coma Scale (GCS) score was used to assess the clinical status at the time of patient admission. Functional outcomes at discharge were assessed using the mRS on a scale of 0–6. Outcomes were dichotomized into good functional outcome, indicated by an mRS of 0–3, and poor functional outcome, indicated by an mRS of 4–6.^{17,18}

Statistical Analysis

Continuous variables with a normal distribution are expressed as mean \pm standard deviation, while not normally distributed data are presented as medians with interquartile ranges, and differences between groups are assessed using the Student's *t*-test or Wilcoxon rank-sum test, respectively. Categorical variables are presented as frequencies with percentages and compared using Pearson's chi-square test or Fisher's exact test. Potential risk factors for new-onset PAF were selected based on medical judgment and were assessed using univariate analysis, and a multivariable regression

model based on a set of all potential predictors ($P > 0.1$) using forward selection was created. The multivariable regression model was used for a subset of patients with NT-proBNP data.

To analyze ICH outcomes at discharge, we performed multivariate logistic regression to investigate whether new-onset PAF was an independent predictor for poor functional outcome. The variables for the models initially included variables related to poor functional outcome in the univariate analysis, and we subsequently performed a forward stepwise selection procedure. All statistical analyses were performed using the R software (version 4.1.1), and significance was set at P values < 0.05 .

Results

Baseline Characteristics of Patients with and without New-Onset PAF

Among 1656 patients who were diagnosed with ICH, 650 patients met the inclusion criteria, and their data were included in the final analysis (Figure 1). Baseline characteristics of 650 patients with ICH stratified by new-onset PAF are summarized in Table 1. New-onset PAF was detected in 24 (3.7%) patients, and all of them admitted within 3 days of symptoms onset. Patients with new-onset PAF were older and more likely to have heart failure, pneumonia, and longer duration of ECM. Regarding the radiological information, the presence of IVH and larger hematoma volume were significantly more frequent in patients with new-onset PAF. Furthermore, patients with new-onset PAF had higher mRS at discharge and lower GCS scores on admission than patients without new-onset PAF. Information on baseline NT-proBNP levels was available for 428 patients. The median NT-proBNP levels were 647 (268–2328) pg/mL and 160 (69–514) pg/mL in patients with and without new-onset PAF, respectively ($P < 0.001$; Table 1).

Risk Factors for New-Onset PAF

The univariable risk factors for new-onset PAF in patients with ICH are shown in Table 2. Older age (odds ratio [OR] per 10-y increase, 2.50 [95% CI, 1.69–3.68]; $P < 0.001$), larger hematoma volume (OR per 10-mL increase, 1.63 [95% CI, 1.19–2.24]; $P = 0.003$), heart failure (OR, 29.48 [95% CI, 9.00–96.59]; $P < 0.001$), and duration of ECM (OR, 1.03 [95% CI, 1.01–1.05]; $P = 0.011$) were significantly associated with new-onset PAF.

The results of the multivariable analyses are presented in Table 3. Significant risk factors included older age (OR per 10-y increase, 2.26 [95% CI, 1.52–3.35]; $P < 0.001$), larger hematoma volume (OR per 10-mL increase, 1.80 [95% CI, 1.26–2.57]; $P = 0.001$), and heart failure (OR, 21.77 [95% CI, 5.52–85.91]; $P < 0.001$).




Figure 1 Study flow chart.

Abbreviations: ICH, intracerebral hemorrhage; AF, atrial fibrillation; IVH, intraventricular hemorrhage.

Table 1 Baseline Characteristics of Patients with Intracerebral Hemorrhage with and without New-Onset PAF

Characteristics	Patients without PAF N=626	Patients with PAF N=24	P value
Gender, female, n (%)	201 (32.1%)	8 (33.3%)	0.899
Age, years (mean \pm SD)	60.2 \pm 14.4	74.0 \pm 12.0	<0.001
ICU admission, n (%)	117 (18.7%)	8 (33.3%)	0.074
Time from symptom onset to admission			
<24 hours	121 (19.3%)	10 (41.7%)	0.016
1–3 day	412 (65.8%)	14 (58.3%)	0.591
3–7 day	93 (14.9%)	0 (0.0%)	0.036
Hematoma location, n (%)			
Lobar	145 (23.2%)	10 (41.7%)	0.065
Deep	396 (63.3%)	12 (50.0%)	0.278
Infratentorial	85 (13.6%)	2 (8.3%)	0.758
Insular damage, n (%)	80 (12.8%)	6 (25.0%)	0.083
Hematoma volume, mL; median (IQR)	10.0 (3.9–25.0)	31.8 (13.3–61.1)	0.002
Presence of IVH, n (%)	189 (30.2%)	13 (54.2%)	0.013
Presence of SAH, n (%)	41 (6.6%)	3 (12.5%)	0.217
Hypertension, n (%)	552 (88.2%)	22 (91.7%)	1.000
Diabetes mellitus, n (%)	145 (23.2%)	5 (20.8%)	0.790
Heart failure, n (%)	7 (1.1%)	6 (25.0%)	<0.001
Pneumonia, n (%)	173 (27.6%)	20 (83.3%)	<0.001
Coronary heart disease, n (%)	44 (7.0%)	4 (16.7%)	0.093
Smoking status: Current, n (%)	152 (24.3%)	4 (16.7%)	0.474
SBP, mmHg; median (IQR)	154 (140–170)	152 (136–162)	0.220
Creatinine, mmol/L; median (IQR)	78.0 (62.0–100.0)	94.0 (64.5–147.0)	0.144
Glucose, mmol/L; median (IQR)	6.0 (5.1–7.6)	6.4 (5.2–8.5)	0.494
Surgery interventions, n (%)	68 (10.9%)	3 (12.5%)	0.738
In-hospital mortality, n (%)	24 (3.8%)	3 (12.5%)	0.072
Length of hospital stay, day; median (IQR)	14 (10–20)	17 (12–32)	0.126
mRS at discharge, median (IQR)	4 (2–4)	4 (4–5)	<0.001
GCS score, median (IQR)	15 (10–15)	9 (5–11)	<0.001
Duration of CEM, day; median (IQR)	9 (5–14)	15 (9–23)	0.005
Total patients with baseline NT-proBNP	405	23	
NT-proBNP, pg/mL; median (IQR)	160 (69–514)	647 (268–2328)	<0.001

Abbreviations: PAF, paroxysmal atrial fibrillation; SD, standard deviation; ICU, intensive care unit; IQR, interquartile range; IVH, intraventricular hemorrhage; SAH, subarachnoid hemorrhage; SBP, systolic blood pressure; mRS, modified Rankin score; GCS, Glasgow Coma Scale; CEM, continuous stroke unit electrocardiography monitoring; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.

Sensitivity Analysis

We performed an analysis of multivariable risk factors for new-onset PAF among 428 patients with baseline NT-proBNP levels, and the results are shown in Table 4. Older age (OR per 10-y increase, 2.16 [95% CI, 1.44–3.24]; $P<0.001$), larger hematoma volume (OR per 10-mL increase, 1.69 [95% CI, 1.17–2.45]; $P=0.005$), heart failure (OR, 8.35 [95% CI, 1.91–36.55]; $P=0.005$), and higher NT-proBNP levels (OR per 1-U increase on log scale, 1.32 [95% CI, 1.00–1.73]; $P=0.049$) were independently associated with new-onset PAF. There was no statistically significant interaction between heart failure and NT-proBNP.

New-Onset PAF and Functional Outcomes at Discharge

The characteristics of the included patients stratified by functional outcomes at discharge are shown in Table 5. Compared with patients with good functional outcome, new-onset PAF was significantly more frequent in patients with poor functional outcome (0.32% vs 6.82%, $P<0.001$).

Table 2 Univariable Regression Model of Risk Factors for New-Onset PAF in Patients with Intracerebral Hemorrhage

Variables	OR (95% CI)	P value
Gender, female	0.95 (0.40–2.25)	0.900
Age (per 10-y increase)	2.50 (1.69–3.68)	<0.001 ^a
Insular damage	2.27 (0.88–5.90)	0.091 ^b
Hematoma volume (per 10-mL increase)	1.63 (1.19–2.24)	0.003 ^a
Coronary heart disease	2.65 (0.87–8.08)	0.088 ^b
Hypertension	1.47 (0.34–6.40)	0.604
Diabetes mellitus	0.87 (0.32–2.38)	0.791
Heart failure	29.48 (9.00–96.59)	<0.001 ^a
Duration of CEM	1.03 (1.01–1.05)	0.011 ^a

Notes: ^aSignificant at $P < 0.05$. ^bSignificant at $P < 0.1$ (cutoff for inclusion in multivariable models).

Abbreviations: OR, odds ratio; CI, confidence interval; CEM, continuous stroke unit electrocardiography monitoring.

Table 3 Multivariate Logistic Regression Analyses of Risk Factors for New-Onset PAF Among Patients with Intracerebral Hemorrhage

Variables	OR (95% CI)	P value
Age (per 10-y increase)	2.26 (1.52–3.35)	<0.001
Hematoma volume (per 10-mL increase)	1.80 (1.26–2.57)	0.001
Heart failure	21.77 (5.52–85.91)	<0.001

Abbreviations: OR, odds ratio; CI, confidence interval.

Table 4 Sensitivity Analysis: Multivariable Analyses of Risk Factors for New-Onset PAF Restricted to Patients with Baseline NT-proBNP Levels ($n = 428$)

Variables	OR (95% CI)	P value
Age (per 10-y increase)	2.16 (1.44–3.24)	<0.001
Hematoma volume (per 10-mL increase)	1.69 (1.17–2.45)	0.005
Heart failure	8.35 (1.91–36.55)	0.005
NT-proBNP (per 1-U increase on log scale)	1.32 (1.00–1.73)	0.049

Abbreviations: OR, odds ratio; CI, confidence interval; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.

Univariable analysis was performed to define the predictors of poor functional outcome at discharge, and the results are shown in Table 6. In the multivariate analysis, new-onset PAF (OR, 10.35 [95% CI, 1.08–98.8]; $P=0.042$), larger hematoma volume (OR per 10-mL increase, 1.30 [95% CI, 1.05–1.60]; $P=0.016$), heart failure (OR, 10.81 [95% CI, 1.09–107.38]; $P=0.042$), pneumonia (OR, 1.93 [95% CI, 1.11–3.34]; $P=0.019$), and lower GCS scores (OR, 0.51 [95% CI, 0.44–0.58]; $P<0.001$) were independent predictors of poor functional outcome in patients with ICH (Table 6).

Discussion

In this study of patients with ICH, 24 (3.7%) cases of new-onset PAF were detected during hospitalization. Older age, larger hematoma volume, and heart failure were associated with a higher risk for new-onset PAF in patients with ICH. When NT-proBNP was available, older age, larger hematoma volume, heart failure, and increased NT-proBNP levels were independent risk factors for new-onset PAF. Furthermore, new-onset PAF was independently associated with poor functional outcome at discharge.

Previous studies have mainly focused on the PAF detection in patients with AIS, especially in those diagnosed with ESUS.^{19,20} Nevertheless, few studies have specifically investigated the prevalence of PAF in patients with ICH. In our study, 3.7% of patients had new-onset PAF detection after ICH during hospitalization. The results presented are comparable to those of a study of unselected patients with AIS and revealed that new AF was detected in 68 of 1717 patients (4.0%) after monitoring using usual

Table 5 Characteristics of Patients with Intracerebral Hemorrhage Stratified by Functional Outcomes at Discharge

Characteristics	Good Outcome N=313	Poor Outcome N=337	P value
Gender, female, n (%)	98 (31.3%)	111 (32.9%)	0.657
Age, years (mean \pm SD)	60.2 \pm 14.1	61.2 \pm 14.9	0.349
New-onset PAF, n (%)	1 (0.3%)	23 (6.8%)	<0.001
ICU admission, n (%)	11 (3.5%)	114 (33.8%)	<0.001
Hematoma location, n (%)			
Lobar	80 (25.6%)	75 (22.3%)	0.370
Deep	188 (60.1%)	220 (65.3%)	0.196
Infratentorial	45 (14.4%)	42 (12.5%)	0.548
Insular damage, n (%)	17 (5.4%)	69 (20.5%)	<0.001
Hematoma volume, mL; median (IQR)	6.0 (2.4–14.0)	17.2 (7.3–41.8)	<0.001
Presence of IVH, n (%)	56 (17.9%)	146 (43.3%)	<0.001
Presence of SAH, n (%)	11 (3.5%)	33 (9.8%)	0.001
Hypertension, n (%)	269 (85.9%)	305 (90.5%)	0.071
Diabetes mellitus, n (%)	67 (21.4%)	83 (24.6%)	0.330
Heart failure, n (%)	1 (0.3%)	12 (3.6%)	0.003
Pneumonia, n (%)	37 (11.8%)	156 (46.3%)	<0.001
Coronary heart disease, n (%)	25 (8.0%)	23 (6.8%)	0.571
SBP, mmHg, median (IQR)	153 (138–169)	156 (140–170)	0.245
Creatinine, mmol/L; median (IQR)	74 (62–94)	82 (63–105)	0.010
Glucometer, mmol/L; median (IQR)	5.5 (4.8–6.8)	6.7 (5.6–8.1)	<0.001
Surgery interventions, n (%)	12 (3.8%)	59 (17.5%)	<0.001
Length of hospital stay, day; median (IQR)	12 (9–15)	16 (12–25)	<0.001
GCS scores, median (IQR)	15 (15–15)	10 (6–14)	<0.001

Abbreviations: SD, standard deviation; PAF, paroxysmal atrial fibrillation; ICU, intensive care unit; IQR, interquartile range; IVH, intraventricular hemorrhage; SAH, subarachnoid hemorrhage; SBP, systolic blood pressure; GCS, Glasgow Coma Scale.

Table 6 Univariable and Multivariable Regression Model of Predictors of Poor Functional Outcome at Discharge in Patients with Intracerebral Hemorrhage

Variables	Univariable OR (95% CI)	P value	Multivariable ^a OR (95% CI)	P value
Gender, female	1.08 (0.77–1.50)	0.657		
Hematoma volume (per 10-mL increase)	2.05 (1.76–2.39)	<0.001	1.30 (1.05–1.60)	0.016
Age (per 10-y increase)	1.08 (0.93–1.25)	0.330		
New-onset PAF	22.85 (3.07–170.20)	<0.001	10.35 (1.08–98.80)	0.042
Heart failure	11.52 (1.49–88.99)	0.019	10.81 (1.09–107.38)	0.042
Pneumonia	6.43 (4.29–9.63)	<0.001	1.93 (1.11–3.34)	0.019
Glucometer	1.11 (1.04–1.19)	0.001		
GCS scores	0.47 (0.41–0.54)	0.001	0.51 (0.44–0.58)	<0.001
Presence of IVH	3.51 (2.45–5.03)	<0.001		
Hematoma location				
Deep	Ref	Ref		
Lobar	0.80 (0.50–1.27)	0.339		
Infratentorial	0.80 (0.55–1.16)	0.241		
Insular damage	4.48 (2.57–7.82)	<0.001		
ICU admission	14.04 (7.38–26.68)	<0.001		
Presence of SAH	2.98 (1.48–6.01)	0.002		
Surgery interventions	5.32 (2.80–10.11)	<0.001		

Notes: ^aVariables from univariate logistic regression with $P < 0.1$ were included in multivariate logistic regression model using a forward stepwise logistic regression analysis and removed with $P > 0.05$.

Abbreviations: OR, odds ratio; CI, confidence interval; PAF, paroxysmal atrial fibrillation; GCS, Glasgow Coma Scale; IVH, intraventricular hemorrhage; Ref, reference; ICU, intensive care unit; SAH, subarachnoid hemorrhage.

diagnostic procedures in the hospital.²¹ Furthermore, another study using at least 24 h of rhythm monitoring in patients with AIS aged ≥ 60 years reported slightly higher rates of new AF detection than our results.²² Although there are no data regarding the differences in the prevalence of new-onset PAF in patients with ICH versus to that in patients with AIS, our study suggests that new-onset PAF is not uncommon in patients with ICH, and this needs to be further investigated.

Our study demonstrated that older age, heart failure and increased NT-proBNP were independently associated with the risk of developing new-onset PAF in patients with ICH. This result is in line with results of previous studies conducted among patients with AIS and in high-risk populations.^{5,7,23–26} Interestingly, we found that larger hematoma volume was significantly associated with the incidence of new-onset PAF after ICH. However, the exact underlying mechanisms remain unclear. Inflammation and its associated immune responses play an important role in AF pathogenesis.²⁷ When ICH occurs, a pronounced inflammatory reaction occurs immediately, which is characterized by the breakdown of the blood–brain barrier,²⁸ activation of microglia, and production of inflammatory factors.^{29–31} Therefore, new-onset PAF may be a complication of systemic inflammation following ICH. Furthermore, autonomic dysregulation has been observed in patients with ICH, with decreased heart rate variability and baroreflex sensitivity.^{32,33} Evidence from clinical studies and animal models revealed that autonomic dysfunction contributes to atrial electrical and structural remodeling, thereby increasing AF inducibility.^{34–38} Altogether, these data indicate that systemic inflammation and autonomic dysfunction may be the important pathophysiology of new-onset PAF in patients with ICH.

Our study showed that the new-onset PAF is an independent predictor of poor functional outcome after ICH. However, it remains unknown whether new-onset PAF in these patients is a direct cause of poor functional outcome or just a marker of disease severity. It is well known that AF can trigger or worsen heart failure, then leading to reduced cardiac output.³⁹ Although the duration of AF episodes was relatively short, the adverse hemodynamic consequences may persist after AF episodes terminated.⁴⁰ Therefore, this effect could be harmful for patients who were diagnosed with new-onset PAF after ICH. In addition, although new-onset PAF remained significantly associated with poor functional outcome after adjusting for potential confounders, the magnitude of the correlation was obviously diminished, indicating that the poor functional outcome can be affected by other risk factors. Consistent with previous studies,^{41–43} we found that hematoma volume, pneumonia, heart failure, and lower GCS scores were strongly correlated with poor functional outcome after ICH. Therefore, they may explain most of the association between new-onset PAF and poor functional outcome. Nevertheless, screening for new-onset PAF among patients with high-risk ICH remains important, and further studies are needed to determine the risk of ischemic stroke and optimal management of these patients.

Our study had some limitations. First, the incidence of PAF after ICH may be underestimated, because of the lack of an AF detection workup and standardized use of long-term cardiac monitoring during hospitalization. Second, although the patients diagnosed with recent cerebral ischemia were not included, we could not exclude the possibility that some patients may have occult PAF before a stroke event. Finally, this was a retrospective, single-center study with a small sample size and low number of events. To further validate these findings, a multicenter prospective study with more patients and a longer follow-up period is required.

Conclusion

In this study, older age, larger hematoma volume, and heart failure were independent risk factors of new-onset PAF in patients with ICH. When data on NT-proBNP were available, increased NT-proBNP levels were also associated with a higher likelihood of detecting new-onset PAF. Furthermore, new-onset PAF was predictive of poor functional outcome after ICH. However, because of the retrospective nature and small sample size of this study, further investigations are needed.

Abbreviations

AF, atrial fibrillation; ICH, intracerebral hemorrhage; PAF, paroxysmal atrial fibrillation; NT-proBNP, N-terminal pro-B-type natriuretic peptide; AIS, acute ischemic stroke; CEM, continuous stroke unit electrocardiography monitoring; IVH, intraventricular hemorrhage; SAH, subarachnoid hemorrhage; SBP, systolic blood pressure; ICU, intensive care unit; GCS, Glasgow Coma Scale; OR, odds ratio; CI, confidence interval.

Ethics Statement

The study was performed according to the Declaration of Helsinki guidelines and was approved by the independent ethics committee of the First Affiliated Hospitals of Sun Yat-sen University. Written informed consent from patients was not required due to its retrospective nature, and all data used in this study was anonymized.

Funding

This study was supported by grants from the National Key R&D Program of China (2017YFC1307500), the Natural Science Foundation of China (Key Program: 82130035; General Program: 81771137, 81971103), the Scientific and Technical Project of Guangdong Province (2017A030303011), Sun Yat-sen University Clinical Research 5010 Program (2018001), the Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Major Neurological Diseases (2017B030314103), Guangdong Provincial Clinical Research Center for Neurological Diseases (2020B111170002), the Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases (2015B050501003), Guangdong Provincial Engineering Center for Major Neurological Disease Treatment, and Guangdong Provincial Translational Medicine Innovation Platform for Diagnosis and Treatment of Major Neurological Disease.

Disclosure

The authors report no conflicts of interest in this work.

References

- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42:373–498. doi:10.1093/eurheartj/ehaa612
- Thijs VN, Brachmann J, Morillo CA, et al. Predictors for atrial fibrillation detection after cryptogenic stroke: results from crystal af. *Neurology*. 2016;86(3):261–269. doi:10.1212/WNL.0000000000002282
- Gladstone DJ, Sullivan LM, Levy D, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the embrace trial. *Stroke*. 2015;46(4):936–941. doi:10.1161/STROKEAHA.115.008714
- Israel C, Kitsiou A, Kalyani M, et al. Detection of atrial fibrillation in patients with embolic stroke of undetermined source by prolonged monitoring with implantable loop recorders. *Thromb Haemost*. 2017;117(10):1962–1969. doi:10.1160/TH17-02-0072
- Bisson A, Bodin A, Clementy N, Babuty D, Lip GYH, Fauchier L. Prediction of incident atrial fibrillation according to gender in patients with ischemic stroke from a nationwide cohort. *Am J Cardiol*. 2018;121:437–444. doi:10.1016/j.amjcard.2017.11.016
- Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. *Lancet*. 2009;373:739–745. doi:10.1016/S0140-6736(09)60443-8
- Friberg L, Rosenqvist M, Lindgren A, Terént A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. *Stroke*. 2014;45:2599–2605. doi:10.1161/STROKEAHA.114.006070
- Putala J, Lehto M, Meretoja A, et al. In-hospital cardiac complications after intracerebral hemorrhage. *Int J Stroke*. 2014;9:741–746. doi:10.1111/ijss.12180
- Horstmann S, Rizos T, Jenetzky E, Gumbinger C, Hacke W, Veltkamp R. Prevalence of atrial fibrillation in intracerebral hemorrhage. *Eur J Neurol*. 2014;21(4):570–576. doi:10.1111/ene.12215
- Prats-Sanchez L, Guisado-Alonso D, Painous C, et al. Insular damage, new-onset atrial fibrillation and outcome after acute intracerebral hemorrhage. *Eur J Neurol*. 2018;25:491–496. doi:10.1111/ene.13522
- Henninger N, Goddeau RP Jr, Karmarkar A, Helenius J, McManus DD. Atrial fibrillation is associated with a worse 90-day outcome than other cardioembolic stroke subtypes. *Stroke*. 2016;47(6):1486–1492. doi:10.1161/STROKEAHA.116.012865
- Du X, Guo L, Xia S, et al. Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China. *Heart*. 2021;107(7):535–541. doi:10.1136/heartjnl-2020-317915
- Masini G, Graham FJ, Pellicori P, et al. Criteria for iron deficiency in patients with heart failure. *J Am Coll Cardiol*. 2022;79:341–351. doi:10.1016/j.jacc.2021.11.039
- Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (esc). *Eur Heart J*. 2010;31(19):2369–2429. doi:10.1093/eurheartj/ehq278
- Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Aspects study group. Alberta stroke programme early ct score. *Lancet*. 2000;355(9216):1670–1674. doi:10.1016/S0140-6736(00)02237-6
- Kothari RU, Brott T, Broderick JP, et al. The ABCs of measuring intracerebral hemorrhage volumes. *Stroke*. 1996;27(8):1304–1305. doi:10.1161/01.STR.27.8.1304
- Hanley DF, Lane K, McBee N, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled clear iii trial. *Lancet*. 2017;389(10069):603–611. doi:10.1016/S0140-6736(16)32410-2
- Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. *N Engl J Med*. 2016;375(11):1033–1043. doi:10.1056/NEJMoa1603460

19. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med*. 2014;370(26):2478–2486. doi:10.1056/NEJMoa1313600
20. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med*. 2014;370(26):2467–2477. doi:10.1056/NEJMoa1311376
21. Haeusler KG, Kirchhof P, Kunze C, et al. Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (mondafis): a randomised, open-label, multicentre study. *Lancet Neurol*. 2021;20(6):426–436. doi:10.1016/S1474-4422(21)00067-3
22. Wachter R, Gröschel K, Gelbrich G, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (find-af randomised): an open-label randomised controlled trial. *Lancet Neurol*. 2017;16(4):282–290. doi:10.1016/S1474-4422(17)30002-9
23. Bahit MC, Sacco RL, Easton JD, et al. Predictors of atrial fibrillation development in patients with embolic stroke of undetermined source: an analysis of the re-spect esus trial. *Circulation*. 2021;144(22):1738–1746. doi:10.1161/CIRCULATIONAHA.121.055176
24. Kim BS, Chun KJ, Hwang JK, et al. Predictors and long-term clinical outcomes of newly developed atrial fibrillation in patients with cardiac implantable electronic devices. *Medicine*. 2016;95(28):e4181. doi:10.1097/MD.00000000000004181
25. Fonseca AC, Brito D, Pinho e Melo T, et al. N-terminal pro-brain natriuretic peptide shows diagnostic accuracy for detecting atrial fibrillation in cryptogenic stroke patients. *Int J Stroke*. 2014;9:419–425. doi:10.1111/ijss.12126
26. Wachter R, Lahno R, Haase B, et al. Natriuretic peptides for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemia--The find-af study. *PLoS One*. 2012;7:e34351. doi:10.1371/journal.pone.0034351
27. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. *Nat Rev Cardiol*. 2015;12:230–243. doi:10.1038/nrcardio.2015.2
28. Keep RF, Xiang J, Ennis SR, et al. Blood-brain barrier function in intracerebral hemorrhage. *Acta Neurochir Suppl*. 2008;105:73–77.
29. Wang J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. *Prog Neurobiol*. 2010;92(4):463–477. doi:10.1016/j.pneurobio.2010.08.001
30. Wang J, Doré S. Inflammation after intracerebral hemorrhage. *J Cereb Blood Flow Metab*. 2007;27(5):894–908. doi:10.1038/sj.jcbfm.9600403
31. Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. *Lancet Neurol*. 2012;11(8):720–731. doi:10.1016/S1474-4422(12)70104-7
32. Sykora M, Diedler J, Rupp A, Turcani P, Rocco A, Steiner T. Impaired baroreflex sensitivity predicts outcome of acute intracerebral hemorrhage. *Crit Care Med*. 2008;36(11):3074–3079. doi:10.1097/CCM.0b013e31818b306d
33. Sykora M, Steiner T, Poli S, Rocco A, Turcani P, Diedler J. Autonomic effects of intraventricular extension in intracerebral hemorrhage. *Neurocrit Care*. 2012;16(1):102–108. doi:10.1007/s12028-011-9637-1
34. Coumel P, Attuel P, Lavallée J, Flammang D, Leclercq JF, Slama R. [The atrial arrhythmia syndrome of vagal origin]. *Arch Mal Coeur Vaiss*. 1978;71(6):645–656. French.
35. Amar D, Zhang H, Miodownik S, Kadish AH. Competing autonomic mechanisms precede the onset of postoperative atrial fibrillation. *J Am Coll Cardiol*. 2003;42:1262–1268. doi:10.1016/S0735-1097(03)00955-0
36. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. *Circulation*. 2002;105(23):2753–2759. doi:10.1161/01.CIR.0000018443.44005.D8
37. Tomita T, Takei M, Saikawa Y, et al. Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease. *J Cardiovasc Electrophysiol*. 2003;14(6):559–564. doi:10.1046/j.1540-8167.2003.02462.x
38. Tan AY, Zhou S, Ogawa M, et al. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. *Circulation*. 2008;118(9):916–925. doi:10.1161/CIRCULATIONAHA.108.776203
39. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. *J Am Coll Cardiol*. 1997;30(4):1039–1045. doi:10.1016/S0735-1097(97)00254-4
40. O'Neill PG, Puleo PR, Bolli R, Rokey R. Return of atrial mechanical function following electrical conversion of atrial dysrhythmias. *Am Heart J*. 1990;120(2):353–359. doi:10.1016/0002-8703(90)90079-D
41. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. *Stroke*. 1993;24:987–993. doi:10.1161/01.STR.24.7.987
42. Fogelholm R, Murros K, Rissanen A, Avikainen S. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. *J Neurol Neurosurg Psychiatry*. 2005;76:1534–1538. doi:10.1136/jnnp.2004.055145
43. Lindner A, Kofler M, Rass V, et al. Early predictors for infectious complications in patients with spontaneous intracerebral hemorrhage and their impact on outcome. *Front Neurol*. 2019;10:817. doi:10.3389/fneur.2019.00817